Marketing - Today Stories

The Publishing group behind the science magazine New Scientist, has closed its dedicated job portal New Scientist Jobs. The site, once a key place for employers to post science and research-oriented vacancies is no longer operating. This however cements PharmiWeb.jobs position as the primary dedicated job board for Life Sciences in Europe. Recruiters and Hiring Managers   Any organisations looking to promote their vacancies with the broadest reach to Life Science professionals across Europe, the USA and Australasia can reach out to PharmiWeb here - https://phrmwb.com/exnewscientistjobs  Job Seekers If you're a job seekers looking for your next Life Science role, PharmiWeb.jobs remains the best place to look - So if if you've not already, register and upload your CV for the best roles. www.…

The UK government has announced a sweeping package of reforms and investment designed to put artificial intelligence at the centre of the country’s economic renewal. The measures include billions of pounds in additional funding and new initiatives aimed at supporting UK businesses, researchers and workers. Key elements of the plan include the creation of new “AI Growth Zones” such as one in South Wales which is expected to bring in more than 5 000 jobs over the next decade, including roles from construction to long-term AI research. Free access to computing resources will be expanded so British researchers and start-ups can train new AI models and deliver breakthroughs in science and industry. A dedicated “Sovereign AI Unit” will be backed with nearly £500 million to support high-potential…

Global life sciences company Bayer has unveiled its new “Science Delivers” campaign, designed to highlight how science shapes everyday life and fosters progress across society. Launched on World Science Day, the initiative includes a wide-reaching advertising push, a public “Declaration on Science,” and interactive experiences that invite people to share personal stories of how science has made a difference in their lives. A central video montage showcases individuals in diverse settings while a voiceover narrates how scientific discovery powers medical breakthroughs, cleaner water, sustainable agriculture, and better energy solutions. The message is clear: for every community and for every tomorrow, science truly delivers. The campaign also features installations and a digital hub where p…

Discovery Park in Sandwich, Kent, has announced the launch of a new specialist sixth form for science-focused students aged 16 to 18. Named Carbon 6 Academy of Science, the school will open in September 2026 and will deliver a dedicated STEM curriculum. Located within the Discovery Park innovation campus, Carbon 6 will give students direct access to professional laboratories and real-world scientific environments. The academy will offer A-levels in Biology, Chemistry, Physics and Mathematics, with options for Further Maths and an Extended Project Qualification. Students will benefit from close connections to the science and pharmaceutical companies based at Discovery Park, gaining opportunities for mentoring, guest lectures, and research placements. The programme is designed to prepare lea…

Novartis announced it will acquire Tourmaline Bio for approximately $1.4 billion, offering $48 per share, a significant premium over recent stock prices. The acquisition will provide Novartis access to pacibekitug, a promising anti-inflammatory drug candidate nearing Phase III trials for atherosclerotic cardiovascular disease. Both companies’ boards have approved the deal, and Novartis will initiate a tender offer to acquire all outstanding shares. The acquisition is expected to close in the fourth quarter of 2025, after which Tourmaline will become an indirect, wholly owned subsidiary of Novartis. The move bolsters Novartis’ growing cardiovascular disease portfolio and aligns with its broader strategic focus. Analysts see the timing as logical, given recent strong Phase 2 data for pacibek…

ramarketing this week announced that it has become the first fully AI-empowered life science marketing agency in the UK and North America.  The agency has invested heavily in AI technology and training over the past year to enable its team to deliver more efficient, effective, and personalized marketing for global clients keen to harness AI capabilities who have consented to its utilization within their strategy and delivery. "We are excited to be at the forefront of AI adoption in life science marketing," said Emma Banks, CEO of ramarketing. "AI is rapidly changing the way we work, and we believe that the companies that embrace AI will be the ones who succeed in the future." The agency is taking a proactive approach to incorporating AI into its day-to-day operations - covering everything…

Edinburgh, Scotland UK, Monday 21st December 2020; Arrayjet, the Scottish-based bio-printing and microarray technology company, has announced the appointment of its new non-executive Chairman. Dr Joe Keegan, a San Francisco-based biotechnology entrepreneur and one of the most respected leaders in the global life sciences industry, will replace Edinburgh-based serial entrepreneur and business strategist Alan Faichney, who is stepping down as Chairman after seven years in the role. Dr. Keegan’s appointed as Chairman is a huge boost for Arrayjet and the wider Scottish life sciences community. Joe joined Arrayjet as a non-exec Director three years ago and has been pivotal in helping the company accelerate a bold global expansion strategy.  He has helped identify and open up new international c…

World Antibiotic Awareness Week aims to increase awareness of global antibiotic resistance and to encourage best practices among the general public, health workers and policy makers to avoid the further emergence and spread of antibiotic resistance.A global action plan to tackle the growing problem of resistance to antibiotics and other antimicrobial medicines was endorsed at the Sixty-eighth World Health Assembly in May 2015. One of the key objectives of the plan is to improve awareness and understanding of antimicrobial resistance through effective communication, education and training.

The Chief Executive of the UK’s pharmaceutical industry association has today warned MPs about the consequences of not agreeing a comprehensive post-Brexit trade deal or an urgent agreement on medicines while the trade talks continue. Richard Torbett told the Commons EU Future Relationship Committee that negotiators must consider the impact of causing unnecessary disruption and delays for UK and EU medicines whilst in the midst of a global pandemic. The Committee heard that companies were working in a constant state of emergency with supply chains under incredible pressure from COVID-19: "We need the bare minimum in order to safeguard risk to the supply chain [for medicines]. If we don’t get this there will be increased complexity, duplication and cost – the last thing we need during COVI…

It’s been 6 months since PharmiWeb, Europe’s largest pharma job board, launched our job board in Australia. Despite the backdrop of COVID-19, a massive thanks go out to all of our clients and all of the talented individuals who have engaged with our site, and come on board!We’re looking forward to the next 6 months as we continue to raise PharmiWeb’s profile across the continent, and help more and more Australian Life Sciences organisations recruit the best talent from PharmiWeb's ever-growing talent pool.If you would like more information regarding Pharmiweb and what our unique services can do for you, contact Sue or Laurel:Sue van Vuurensue.vanvuuren@pharmiweb.comTel: +61 (0) 468 625 626Laurel Steynlaurel.steyn@pharmiweb.comTel: +61 (0) 423 665 441Find Out More Here #pharmiweb #pharmajob…

After months of waiting, the official NHS COVID-19 contact tracing app for England and Wales is now available.   Protect your loved ones with the official NHS COVID-19 contact tracing app for England and Wales. It's the fastest way of knowing when you're at risk from coronavirus (COVID-19). The quicker you know, the quicker you can alert your loved ones, and your community.  The more of us that use it, the better we can control coronavirus. Protect your loved ones. Please download the app.

Responding to the news that the Covid-19 vaccine trial being run by Oxford University in conjunction with AstraZeneca has been halted for a second time, Kate Shaw, CEO of Innovative Trials, a clinical trials patient recruitment company, hoped it would not deter people from participating in clinical trials, either now or in the future. Shaw said: “I wish the clinical trial participant in question a swift recovery, but it’s important to note that a temporary halt on research is not uncommon and does not automatically mean a medicine is unsafe. Many treatments and vaccines can experience a pause during their development, even ones that are ultimately successful and brought to market.  “This news highlights the need for greater public awareness of what clinical research involves in order to av…

David Spencer-Percival founded Spencer Ogden and Huntress - two globally successful recruitment firms Life Science People launches with a commitment to boost employment opportunities post Covid-19 London, 01 September 2020: David Spencer-Percival, serial entrepreneur and founder of two globally successful recruitment businesses, Huntress and Spencer Ogden, is launching his latest venture, Life Science People. With a personal investment of £2m and an initial team of 20, Spencer-Percival’s team have set their sights set on ambitious growth, with plans to have a London office of 100 by December, and nine international offices within five years. In launching Life Science People he continues his commitment to hiring and training graduates, something he has maintained throughout all of his ven…

New UK fund cornerstoned by £50 million investment from the British Business Bank, through its Enterprise Capital Funds (ECF) programme Epidarex Capital III UK LP will invest in new life science companies from emerging research hubs across the UK, including spinouts from highly regarded universities Edinburgh, UK, 22 June 2020 - Epidarex Capital (“Epidarex”), a transatlantic life science venture firm, announces that it has closed Epidarex Capital III UK LP (the “Fund”) at £102.1 million. The Fund will build new life science companies based on world-class research and innovation from emerging hubs across the UK, including spinouts from highly regarded universities. Typical initial investments will range from £2 million to £5 million. The new Fund has been cornerstoned by the British Busin…

The House of Lords International Agreements Sub-Committee has today launched its first call for evidence, seeking views on the ongoing UK-US trade negotiations. The committee is seeking evidence on the full range of areas being negotiated with the US, with an initial focus on agriculture and food safety, healthcare and drug pricing, and digital trade and services. The committee is asking for submissions of written evidence to be received by Friday 26 June, but the call for evidence will remain open throughout the negotiations. Lord Goldsmith, Chairman of the Internaional Agreements Sub-Committee, said: “The International Agreements Sub-Committee has been established to scrutinise how the Government negotiates new international agreements for a post-Brexit UK. This includes new trade deals.…

PharmiWeb Ltd, owners of Europe's largest Pharma Job Board, are pleased to announce that they have launched their latest job board for Pharma and Life Science Jobs in Australasia. The new job board will focus on the Pharma, Life Sciences & Medical Devices sector in Australasia and will give the region's job seekers a new dedicated website for their job hunting.    The site is built upon on the well-established Madgex job board platform already used by many major organisations globally, and ensures it will be continually updated with new technological advances such as AI and machine learning and new features that will help candidates find the best jobs and recruiters find the best candidates. For life science candidates, it provides the perfect platform to help them with their career de…

London, United Kingdom, Tuesday 10 March - George Health, a profit-for-purpose company, today announces £27 million / $35 million of new financing to accelerate the commercialisation of affordable drug treatments and technologies for some of the world’s biggest killers. This funding round was led by Bupa Australia, Federation Asset Management and the Australian Government-backed Medical Research Commercialisation Fund Biomedical Translation Fund (MRCF BTF), managed by Brandon Capital Partners. The investments are set to fast-track the growth of George Health Enterprises, the commercial arm of the world-leading George Institute for Global Health, and George Medicines, its late-stage drug development company. George Health Enterprises will receive almost £17 million from Federation Asset Man…

– Gilead Gains Forty Seven’s Investigational Immuno-Oncology Therapy in Multiple Clinical Studies for Diseases Including Myelodysplastic Syndrome, Acute Myeloid Leukemia and Diffuse Large B-Cell Lymphoma – – Transaction Supports Gilead’s Strategic Focus in Oncology and Gives Access to Potential New First-in-Class Program and Innovative Pipeline – FOSTER CITY, Calif. & MENLO PARK, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Forty Seven, Inc. (Nasdaq: FTSV) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Forty Seven for $95.50 per share in cash. The transaction, which values Forty Seven at approximately $4.9 billion, was unanimously approved by both the Gilead and Forty Seven Boards of Directors and…

CROMSOURCE announced today the achievement of a significant milestone in the digital management of clinical research projects for their clients. In February 2020 CROMSOURCE initiated the 1000th trial to be managed within the advanced TheClinical digital environment. TheClinical, developed by Techorizon, consists of customisable, integrated modules dedicated to the efficient digital management of every aspect of clinical research and development projects. ‘Digitalisation is a key foundation of our working philosophy, and has been a significant source of our investment for many years’, commented CROMSOURCE CEO, Dr. Oriana Zerbini. ‘Our adoption and development of digital technologies provides our clients with benefits in efficiency, quality and visibility on their projects.’ ‘Our clients typ…